Abstract Titles

Skip to Late-Breaking Abstracts »

All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Onsite Posters

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.

ePosters

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.


Search word or phrase:

# Type Title Authors Category Keywords
97 Poster Presentation High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies David Langan, PhD; Jourdain Lemaster; Lauren Suarez, PhD; Pratima Kunwar, PhD; Sojung Kim, PhD; Mathias Oelke, PhD Cellular Therapies Adoptive immunotherapy;T cell;Tumor antigens
98 Poster Presentation NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy Sarah Whelan, PhD; Jennifa Gosling, MSc; Monisha Mani, MSc; Frederick Cohen, PhD; Austin Tenn-McClellan, BS; Janine Powers, PhD; Gwenn Hansen, PhD; Michael T. Lotze, MD; Arthur T. Sands, MD, PhD Cellular Therapies Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
99 Poster Presentation T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants Daniel Hirschhorn, PhD; Sadna Budhu, PhD; David Schröder, MD, PhD; Lukas kraehenbuehl; Anne-Laurent Flammar; Andrew Chow, MD, PhD; Isabell Schulze; Sara Schad, BS; Jacob Ricca; Billel Gasmi; Olivier De Henau; Levi M. Mangarin, BS; David Redmond; Czrina Cortez, BS; Cailian Liu, MD; Aliya Holland; Mathieu Gigoux, PhD; Asrhi Arora; Katherine S. Panageas, PhD; Gabrielle Rizzuto; Jean Albrengues, PhD; Mikala Egeblad, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD Cellular Therapies Adoptive immunotherapy;Checkpoint blockade;Costimulation;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
100 Poster Presentation Redirecting glucose flux during in vitro expansion improves the in vivo performance of adoptive T cell therapies for cancer Andrew Frisch, BS; Yupeng Wang, BD; Yiyang Wang, N/A; Konstantinos Lontos, MD; Dayana Rivadeneira, PhD; Greg M. Delgoffe, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
101 Poster Presentation Expansion of tumor-infiltrating lymphocytes (TIL) using static bag for the clinical manufacturing rapid expansion protocol (REP) process Kenneth Onimus; Adrian Wells; Nermin Gerges; Courtney Herman; Shwetha Lakshmipathi; Viktoria Gontcharova, PhD; Joe Wypych; Arvind Natarajan; Anand Veerapathran Cellular Therapies Adoptive immunotherapy;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
102 Poster Presentation The deep phenotype characterization of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) T Cells allows to identify their subset complexity and to optimize their manufacturing Cristina Maccalli, PhD; Asma Al-Sulaiti; Mohammed El-Anbari, PhD; Moza Al Khulaifi, BSc; Mohammed Toufiq; Rebecca Mathew; Chiara Cugno, MD; Sara Deola, MD; Suruchi Mohan, MD; Damilola Olagunju; Chiara Bonini, MD; Monica Casucci, PhD; Sara Tomei, PhD; Damien Chaussabel, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell lineages
103 Poster Presentation Quality improvement of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and inhibition of tyrosine kinase Yasunori Amaishi, MS; Izumi Maki; Maiko Sugizaki; Kenichiro Mihara, M.D., Ph.D.; Sachiko Okamoto, PhD; Junichi Mineno, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell;Targeted therapy;Tumor antigens
104 Poster Presentation Development and characterization of human chimeric antigen receptor Monocytes (CAR-Mono), a novel cell therapy platform Daniel Blumenthal, PhD; Linara Gabitova, PhD; Brett Menchel; Patricia Reyes-Uribe; Andrew Best, BS, MS; Michael Lynch; Sotheavy Chhum; Maggie Schmierer; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD Cellular Therapies Adoptive immunotherapy;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors
105 Poster Presentation 4-1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells Emiliano Roselli, Ph.D.; Justin C. Boucher; Gongbo Li; Hiroshi Kotani; Kristen Spitler; Kayla M. Reid, M.S.; Yannick Bulliard; Nhan Tu; Sae Bom Lee; Bin Yu; Frederick L. Locke, M.D.; Marco L. Davila, M.D., Ph.D. Cellular Therapies Adoptive immunotherapy;Bispecifics;CAR T cells
106 Poster Presentation Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel) Archana Brahmandam, MS; Jim J. Qin, BS; Susan Kim; Yue Jiang; Brook Barajas; Soraya Carrancio; Leanne Peiser Cellular Therapies CAR T cells;Cytokine;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy
107 Poster Presentation Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity Eytan Breman, MSc; Ann-Sophie Walravens; Isabelle Gennart; Amelie Velghe; Thuy Nguyen; Benjamin Violle; Fanny Huberty; Nancy Ramelot; Laure Twyffels; Emilie Gauthy; Hannes Iserentant; David E. Gilham, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
108 Poster Presentation Fast and accurate prediction of optimal CAR T-cell function using z-Movi® Cell Avidity Analyzer Will Singleterry, Phd; Andrea Candelli, PhD; Rogier M. Reijmers, PhD; Jens Eberlein, PhD Cellular Therapies CAR T cells;T cell;Tumor antigens;Tumor evasion
110 Poster Presentation IL-2 variant improves CAR-T functionality and efficacy against solid tumors Qi Dong, Msc; Wenjie Yin, Ph.D.; Pengfei Jiang, Ph.D.; Manli Yin; Tao Wang; Ping Wang; Xinxin Wang, Ph.D.; William Wei Cao, Ph.D.; Lianjun Shen, Ph.D. Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
111 Poster Presentation Armored CAR T Cells Secreting 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor for Enhanced Solid Tumor Efficacy Zachary S. Dunn, MS; Yun Qu, Doctorate; Melanie MacMullan; Xianhui Chen, Doctorate; Gunce Cinay; Pin Wang, Doctorate Cellular Therapies Adoptive immunotherapy;Antibody;Bispecifics;CAR T cells;Checkpoint blockade;Costimulation;Solid tumors;T cell;Tumor microenvironment
112 Poster Presentation Tumor-specific Reactivity and Effector Function of Chimeric Antigen Receptor Engineered Macrophages Targeting MUC1 Seth H. Eisenberg; Amy A. Powers, MS; Jason C. Lohmueller, PhD; James D. Luketich, MD; Rajeev Dhupar, MD; Adam C. Soloff, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Tumor antigens
113 Poster Presentation CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition Chao Guo, PhD; Yanying Fan; Alexander Aronov; Luxuan Buren, Ph.D.; Ming-Hong Xie, MD; Ivan H. Chan, PhD; Sasha Lazetic; James B. Trager, PhD Cellular Therapies NK/NKT cell;Tumor microenvironment
115 Poster Presentation An NFAT Promoter Based Fluorescent Jurkat Cell Platform for High-Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs Brikena Gjeci, MS; Sadik H. Kassim, PhD; Julian Scherer Cellular Therapies CAR T cells
116 Poster Presentation Development of Logic Gated CAR-NK cells for the treatment of solid tumors Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Marcus Gainer; Alyssa Mullenix; Miguel Palermo; Derrick Lee; Frances D. Liu, PhD; Russell M. Gordley, PhD; Chen-Ting Lee, PhD; Assen Roguev, PhD; Niran Almudhfar; Mengxi Tian; Gary Lee, PhD Cellular Therapies Immune toxicity;NK/NKT cell;Solid tumors;Tumor antigens
117 Oral Presentation FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy. John Goulding, PhD; Bryan Hancock, PhD; Robert Blum, MS; Moyar Ge, PhD; Svetlana Gaidarova, MS; Paul Rogers, PhD; Sajid Mahmood, PhD; Rina Mbofung, PhD; Wen-I Yeh, PhD; Bi-Huei Yang, PhD; Chia-Wei Chang, PhD; Brian Groff, BS; Soheila Shirinbak, PhD; Joy Grant; Martin Hosking, PhD; Mochtar Pribadi; Yijia Pan; Hui-Yi Chu; Shohreh Sikaroodi, PhD; Lauren Fong, PhD; Nicholas Brookhouser, PhD; Fernanda Rodrigues Cugola, PhD; Ramzey Abujarour, PhD; Janel Huffman, MS; Pei-Fang Tsai, PhD; Antonio Fernandez-Perez, PhD; Karina Palomares, PhD; Natalie Marquez-Solorzano, MS; Riya Kanherkar, PhD; Andrew Burns, PhD; Aidan Keefe, MS; Samvel Nazaretyan, BS; Christine Chen, PhD; Raedun Clarke, PhD; Thomas Dailey, BS; Miguel Meza, BS; Jason O'Rouke, PhD; Jerome Bressi, PhD; Tom Lee; Ryan Bjordahl, PhD; Lucas Ferrari de Andrade, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD Cellular Therapies Adoptive immunotherapy;Chemotherapy;Clinical study;Leukemia/Lymphoma;NK/NKT cell;Radiotherapy;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion
118 Poster Presentation Development of Claudin 18.2 TAC T cells for the treatment of gastric cancer christopher CW. Helsen, PhD; Tania Benatar, PhD; Philbert IP, PhD; Stacey Xu, PhD; Laura Shaver; Thanyashanthi Nitya-Nootan, MSc; Andreas G. Bader; Prabha Lal, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell
119 Poster Presentation ADI-002: an IL-15 armored allogeneic “off-the-shelf” Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3) Amani Makkouk, PhD; Xue (Cher) Yang; Taylor Barca; Anthony Lucas; Mustafa Turkoz; Jonathan Wong; Kevin P. Nishimoto; Mary M. Brody; Maryam Tabrizizad; Smitha Gundurao; Lu Bai; Arun Bhat; Zili An; Stewart Abbot; Daulet Satpayev; Marissa Herrman Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens
120 Poster Presentation Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors Martin Hosking, PhD; Soheila Shirinbak, PhD; Joy Grant; Yijia Pan; Angela Gentile; Amit Mehta; Bjoern Gaertner, PhD; Bishwas Shrestha, PhD; Mochtar Pribadi; Jason ORourke, PhD; Alec Witty; Tom Lee; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Chemokine;Chemotherapy;Radiotherapy;Solid tumors;T cell;Tumor microenvironment
121 Poster Presentation ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging Jingmei Hsu, MD, PhD; Eric von Hofe, PhD; Michael Hsu, MD, PhD; Koen Van Besien, MD; Thomas Fahey, MD; Jana Ivanidze, MD, PhD; Janusz Puc, PhD; Karrie Du, PharmD; Moonsoo M. Jin, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
122 Poster Presentation A powerful, precise targeting system controlled by tumor deletions transforms CEA and MSLN CAR-T cells into tumor-selective agents Agnes Hamburger; Han Xu, PhD; Yuta Ando; Grace Asuelime; Kristian Bolanos-Ibarra; Mark Daris, PhD; Kiran Deshmukh; Breanna DiAndreth; Fernando Fisher; Grant Gabrelow; Maria Imun; David Ju; Wen-Hua Lee; Chuck Li; Edwin Liu; Aaron D. Martin, M.A.; Michele Mcelvain; Jee-Young Mock; Daniel Nampe; Martin Naradikian; Mark Sandberg, PhD; Sanam Shafaattalab; Shruti Sharma; Talar Tokatlian; Dora Toledo-Warshaviak; Xueyin Wang, PhD; Lu-Min Wong; Alexander Kamb, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor antigens
123 Poster Presentation P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor Yan Zhang, Ph.D.; Anna K. Kozlowska, Ph.D.; Jacqueline Fritz; Yingying Zhao; Claudia Palomino La Torre; Stacey Cranert, Ph.D.; Steven Wang; Rebecca Codde; Elvira Argus, Ph.D.; Samad Ibitokou, Ph.D.; Vanitra Richardson; Sumiti Jain, Ph.D.; Maximilian Richter, Ph.D.; Deepak Patil, Ph.D.; Yening Tan; Min Tong; Lu Yao, Ph.D.; Majid Ghoddusi, Ph.D.; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, Ph.D. Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
124 Poster Presentation Functionalizing CAR T cells for selective proliferation and dual-targeting using the meditope technology Cheng-Fu Kuo, MS; Yi-Chiu Kuo; Miso Park; Zhen Tong; Brenda Aguilar; Agata Xella; Vanessa Salvary; Stephen J. Forman; John C. Williams, PhD; Christine Brown, PhD Cellular Therapies Antibody;CAR T cells;T cell
125 Poster Presentation Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma Jessica Lake, MD MPH; Kevin Winkler, BA; Alexander Harrant, BS; Ashley Yingst, MS; Kristin Schaller, PhD; Eric Hoffmeyer, BS; Madeline Larson, BS; Dejene Tufa, PhD DVM; Laura Cobb, MD; Dallas Jones, PhD; Michael Verneris, MD Cellular Therapies CAR T cells;Chemokine;Pediatric tumors;Radiotherapy;Solid tumors;T cell
126 Poster Presentation Regional administration of IL-12 endowed CAR T cells effectively targets systemic disease Hee Jun Lee, BA; Cody Cullen; John P. Murad; Jason Yang; Wen-Chung Chang; Stephen J. Forman; Saul Priceman, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell
127 Poster Presentation CAR T cells targeting the integrin alpha v beta 3 exhibit robust anti-tumor responses against diffuse intrinsic pontine glioma and glioblastoma Dustin A. Cobb, PhD; Jacopo de Rossi; Lixia Liu; Erin An; Daniel W. Lee, III, MD Cellular Therapies CAR T cells;Pediatric tumors;Solid tumors;T cell;Targeted therapy
128 Poster Presentation KIR haplotype can inform donor selection production of allogeneic memory-like CAR NK cells for clinical application Hadia Lemar, BS; Anmol Vohra, MS; Ming-Hong Xie, MD; Ivan H. Chan, PhD; Sasha Lazetic; James B. Trager, PhD Cellular Therapies Cytokine;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy
129 Poster Presentation Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors Hoyong Lim, PhD; Amanda Medcalf; Lisa Guerrettaz, PhD; Eun Ji Choi; Hansol Kim; Bitna Yang; Eun Ji Kim; Eun-Sol Lee; Jeong Min Kim; Yusun Kim; Bokyung Min; Sang-Min Paik; Hyeong Jin Nam; Seungryel Han; Srinivas Somanchi, PhD; Eugene Helsel; Jason Litten, MD; Peter Flynn, PhD; Heather Raymon, PhD; Yu-Kyeong Hwang, PhD Cellular Therapies NK/NKT cell;Solid tumors
130 Oral Presentation Engineered natural killer cells reactively block TIGIT and CD73 in the GBM microenvironment Kyle B. Lupo, BS; Sandro Matosevic, PHD Cellular Therapies Adoptive immunotherapy;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment
131 Poster Presentation Genetic disruption of negative immune regulators to enhance CAR-T efficacy against solid tumors David Mai, BS; Omar S. Johnson; Carl H. June, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
132 Oral Presentation HLA-independent T cell receptors effectively target low abundance antigens Jorge Mansilla-Soto, PhD; Justin Eyquem; Sascha Haubner; Mohamad Hamieh; Judith Feucht; Noémie Paillon; Andres E. Zucchetti; Zhuoning Li; Maria Sjöstrand; Pieter L. Lindenbergh; Michelle Saetersmoen; Mathieu Maurin; Archana Iyer; Anton Dobrin; Andreina Garcia Angus; Matthew M. Miele; Zeguo Zhao; Theodoros Giavridis; Sjoukje JC. van der Stegen; Fella Tamzalit; Morgan Huse; Ronald C. Hendrickson; Claire Hivroz; Michel Sadelain Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell
133 Poster Presentation CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity Jonathan Terrett, PhD; Brigid Mcewan, MA; Daniel Hostetter; Luis Gamboa; Meghna Kuppuraju; Mohammed Ghonime; Robert Chain; Zinkal Padalia; Demetrios Kalaitzidis Cellular Therapies CAR T cells
135 Poster Presentation Identification and Characterization of an allogeneic iNKT-CAR targeting BCMA Xavier Michelet, PhD; Eleni Chantzoura, PhD; Efrat Altman-Sharoni; Martyna Popis; Reed Masakyan; Paul Ibbett; Deborah Wright; Moira Pinzan Rossi; Marc A. Van Dijk, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy
136 Poster Presentation ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors Xianhui Chen, PhD; Jiangyue Liu; Shuai Yang; Amogh Oke; Sarah Davies; Bryan Ruiz-Juarez; Yannick Bulliard; Cokey Nguyen Cellular Therapies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
137 Poster Presentation Development of anti-Mucin1 CAR-T against solid tumors Jihyun Lee, Ph.D.; Areum Park, Ph. D.; Jungwon Choi; Dae Gwan Yi, Ph. D.; Hee Jung Yang, Ph. D.; Hae-youn Lee, Ph.D.; Eurim Song; Sung Woong Jang, Ph.D.; Hyoju Yi, Ph.D.; Heedong Park; Eun-ji Jeun, Ph.D.; Minjeong Park; Peter S. Hong, Ph.D. Cellular Therapies CAR T cells;T cell
138 Poster Presentation Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors Eigen Peralta; Emily Carron, PhD; Hui-Yi Chu; Lorraine Loter; Natalie Navarrete; Arvin Tam; Amit Mehta; Dan Lu; Philip Chu; Kenyon Lyon; Yijia Pan; Mochtar Pribadi; Alec Witty; Tom Lee; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment
139 Poster Presentation Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors Stefano Pierini, PhD; Michael Klichinsky, PharmD, PhD; Rashid Gabbasov, PhD; Alison Worth; Ilyssa Ramos; Daniel Blumenthal, PhD; Linara Gabitova, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Michael Ball; Yumi Ohtani, PhD Cellular Therapies Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Tumor microenvironment
140 Poster Presentation Allogeneic CAR T cells with deoxycytidine kinase knockdown demonstrate resistance to fludarabine Michelle B. Pires, MS; Aaron J. Martin, PhD Cellular Therapies CAR T cells;T cell
142 Poster Presentation Enhanced antitumoral activity of HER2-CAR-Ts in comparison to Trastuzumab in a live cell imaging supported 3D assay Katharina Schaich, MSc; Gemma Moiset; Sophie C. Vermond, MSc; Monique Hazenoot; Kanstantsin Lashuk; Eva Oswald, PhD; Sanne Holt; Julia Schuler, DVM PhD Cellular Therapies Antibody;CAR T cells;Solid tumors;T cell;Tumor antigens
143 Poster Presentation Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment Cecile Schiffer-Mannioui; Sophie Leduc; Isabelle Chion-Sotinel; Diane le Clerre; Valérie Guyot; Marco Rotondi; Roman Galetto, PhD; Agnès Gouble Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
144 Poster Presentation SIRP⍺ deficient CAR-Macrophages exhibit enhanced anti-tumor function and bypass the CD47 immune checkpoint Chris Sloas, PhD; Rashid Gabbasov, PhD; Nicholas R. Anderson, PhD; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD; Yumi Ohtani, PhD Cellular Therapies Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment
145 Poster Presentation Comparison of CAR-T cell manufacturing platforms reveals distinct phenotypic and transcriptional profiles Hannah W. Song, PhD; Lipei Shao, PhD; Michaela Prochazkova; Adam Cheuk, PhD; Ping Jin, PhD; David F. Stroncek, MD; Javed Khan, MD; Steven L. Highfill, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Clinical study;Gene expression;Solid tumors;T cell
146 Poster Presentation Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy Mikhail Steklov; Benjamin Lecalve; Jerome Marijse; Fanny Huberty; Nancy Ramelot; Celine Jacques-Hespel; Hannes Iserentant; Eytan Breman, MSc; David E. Gilham, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell
147 Poster Presentation Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control Hubert Tseng, PhD; Yan Zhang, Ph.D.; Stacey Cranert, Ph.D.; Maximilian Richter, Ph.D.; Karl Marquez; Jing Qiu; Benjamin Cho; Yening Tan; Min Tong, MS; Christine Domingo, BS; Leslie A. Weiss, M.S.; Elvira Argus, Ph.D.; Jessica Sparks; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell
148 Poster Presentation Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro Sophie C. Vermond, MSc; Monique Hazenoot; Rene McLaughlin; Sabrina de Munnik; Marco Guadagnoli; Gemma Moiset; Sanne Holt; Marijn Vlaming Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens
149 Poster Presentation In vitro efficacy studies to support engineered T cell therapies Sabrina de Munnik; Monique Hazenoot; Sophie C. Vermond, MSc; Rene McLaughlin; Marco Guadagnoli; Gemma Moiset; Sann Holt; Marijn Vlaming Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;T cell;Targeted therapy;Tumor antigens
150 Poster Presentation Targeted delivery of a PD-L1-blocking scFv by CAR-NK cells shows potential as a new approach to immunotherapy for glioblastoma Jiao Wang, PhD; Sandro Matosevic, PHD Cellular Therapies Adoptive immunotherapy;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment
151 Poster Presentation Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application Michael I. Whang, PhD; Ming-Hong Xie, MD; Kate Jamboretz, MS; Hadia Lemar, BS; Chao Guo, PhD; Nafees Rahman, PhD; Ivan Chan, PhD; Erik M. Whiteley, PhD; Ralph Brandenberger, PhD; Sasha Lazetic; James B. Trager, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy
152 Oral Presentation Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages Taylor L. Wilson, BS; Hyunjin Kim, PhD; Jeremy C. Crawford, PhD; Ching-Heng Chou, PhD; Deanna Langfitt, PhD; E. Kaitlynn Allen, PhD; Timothy Lockey, PhD; Michael Meagher, PhD; Aimee C. Talleur, MD; Stephen Gottschalk, MD; Paul G. Thomas, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Gene expression;T cell;T cell lineages
153 Poster Presentation Nanoscale, antigen-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment Zhifen Yang, Dr.; Francesco M. Marincola, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
154 Poster Presentation Context-dependent reversible modulation of cJUN expression by CAR T cells for cancer treatment Zhifen Yang, Dr.; Francesco M. Marincola, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
155 Poster Presentation CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies Yinmeng (Amy) Yang, PhD; Ryan Murray; Adam J. Camblin, PhD; Faith Musenge; Lindsey Coholan; MarkVic Naniong; David Sweezy; Scott Haskett; Lauren Young; Yingying Zhang, PhD; Amanda Costa; Hui Wu; Alden Ladd; Luis Barrera, PhD; Lisa Schlehuber, PhD; Sarah Smith; Yeh-Chuin Poh, PhD; Giuseppe Ciaramella, PhD; Jason Gehrke, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell
156 Poster Presentation RBC-Derived, Activating Antigen Carriers (SQZ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo Katarina Blagovic, PhD; Carolyne Smith, PhD; Lindsay Moore; Emrah Ilker Ozay, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD Cellular Therapies Adoptive immunotherapy;Chemotherapy;Immune adjuvant;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
157 Poster Presentation Lymph node targeted boosting with cognate Amphiphile-peptide vaccines enhances TCR-T Cell therapy to eradicate solid tumors Dylan J. Drakes, PhD; Abdulraouf M. Abbas, M.Sc.; Jacqueline Shields; Peter C. DeMuth, PhD Cellular Therapies Adoptive immunotherapy;Immune adjuvant;Solid tumors;T cell;Targeted therapy;Vaccine
158 Poster Presentation Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killing Kate M. Rochlin, PhD; Amber Jones; Lawrence S. Lamb, Jr., PhD; Anita Hjelmeland, PhD Cellular Therapies Checkpoint blockade;Chemotherapy;Gene expression;Solid tumors;T cell;Tumor antigens
159 Poster Presentation Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers Irene Raitman, PhD; John Fitzgerald, BS; Valentina Rousseva, MS; Salvatore Rotondo, MS; Xuan Guo, PhD; Hemlata Rana, MS; Andrea DiFiglia, BS; Tanel Mahlakoiv, PhD; Shuyang He, PhD; Lin Kang, PhD; Robert Hariri, MD PhD; Xiaokui Zhang, PhD Cellular Therapies Antibody;NK/NKT cell;Solid tumors;Targeted therapy
160 Poster Presentation Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors Paul D. Rennert, PhD; Lan Wu, PhD; Lihe Su, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD Cellular Therapies Adoptive immunotherapy;Bispecifics;CAR T cells;Tumor antigens
161 Poster Presentation Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors Peter M. Sullivan, PhD; Rajesh Kumar, PhD; Wei Li, PhD; Lingyang Wang, PhD; Yue Zhang, MS; Adam Cheuk, PhD; Javed Khan, MD; Dimiter S. Dimitrov, PhD; Rimas J. Orentas, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Myeloid cells;Pediatric tumors;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma
162 Poster Presentation Nicotinamide rejuvenates ex-vivo expanded natural killer cells and enhances their tumor killing capacity Aviad AP. Pato, Dr, PhD; Astar Hailu; Nurit Brickman; Dima Yackoubov; Frank S. Cichocki, PhD; Amnon Peled, PhD; Yona Geffen, PhD; Avishay Edri, PhD; Ronit Simantov, MD; Tracey Lodie, PhD; Julia Rifman, PhD; Orit Berhani-Zipori, PhD; Aviad Pato Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Solid tumors
163 Poster Presentation Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression Gagan Bajwa; Justin T. Gunesch; Inbar Azoulay-Alfaguter; Melinda Mata; Ali Mohamed; Mamta Kalra; Steffen Walter Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Costimulation;Cytokine;T cell;Targeted therapy;Tumor microenvironment
164 Poster Presentation Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells Frank Borriello, MD, PhD; Joshua Keegan; James A. Lederer, PhD Cellular Therapies Adoptive immunotherapy;NK/NKT cell;T cell
165 Poster Presentation Generating Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic Cell Squeezing Devin Bridgen, PhD; Arindam Bhattacharjee; Colin J. Thalhofer, PhD; Ryan D. Montler, MBA; Andrew D. Weinberg, PhD; Armon Sharei, PhD; Jonathan Gilbert, PhD Cellular Therapies Cytokine;RNA;T cell;Tumor infiltrating lymphocytes (TILs)
166 Poster Presentation Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo Rachel A. Burga, PhD; Mithun Khattar, PhD; Scott Lajoie; Kyle Pedro, PhD; Colleen Foley; Alonso Villasmil Ocando; Jack Tremblay; Benjamin Primack; Meghan Langley, BS; Dan Thornton; Stanley Tam; Emily Brideau; Theresa Ross; Gwen Wilmes, PhD; Sunandan Saha, PhD; Gabriel Helmlinger, PhD; Jeremy Tchaicha, PhD; Dhruv Sethi, PhD; Michelle L. Ols, PhD; Gary Vanasse, MD; Shyam Subramanian, PhD; Jan ter Meulen, MD, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
167 Poster Presentation High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest Praveen D. Chatani, MD; Frank J. Lowery, PhD; Neilesh B. Parikh, M.D.; Rami Yossef, PhD; Victoria Hill, PhD; Zhiya Yu, PhD; Todd D. Prickett, PhD; Jared Gartner; Biman C. Paria, M.S.; Satyajit Ray; Maria Florentin; Paul F. Robbins, PhD; Sri Krishna, PhD; Steven A. Rosenberg, MD, PhD Cellular Therapies Adoptive immunotherapy;Biomarkers;Clinical study;Neoantigens;T cell;T cell lineages;Tumor antigens
168 Poster Presentation Expanding and characterizing tumor infiltrating lymphocytes from myxofibrosarcoma and undifferentiated pleomorphic sarcoma Jacky HK. Chen, HBSc; Jay S. Wunder, MD., MSc; Kim Tsoi, MD., PhD; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Costimulation;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
169 Poster Presentation Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo Frank S. Cichocki, PhD; Jianfang S. Ning; Zachary B. Davis, PhD; Hongbo S. Wang; Katie S. Tuininga; Ryan Bjordahl, PhD; Paul Rogers, PhD; Moyar Ge, PhD; Tom Lee; Bob Valamehr, PhD; Clark C. Chen, MD; Jeffrey S. Miller, MD Cellular Therapies Adoptive immunotherapy;NK/NKT cell
170 Poster Presentation Novel gene editing approach to enhance CD38-directed antitumor activity of primary human natural killer cells Joseph A. Clara, MD; Emily Levy; Robert Reger; Mala Chakraborty; David Allan; Richard W. Childs, M.D. Cellular Therapies Adoptive immunotherapy;Antibody;NK/NKT cell;Targeted therapy
171 Poster Presentation Targeting the Immunomodulatory Roles of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 on Natural Killer Cells in Glioblastoma Tram N. Dao; Sandro Matosevic, PHD Cellular Therapies Adoptive immunotherapy;Metabolism;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
172 Poster Presentation Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering Samantha M. Fix, PhD; Marie-Andrée Forget; Donastas Sakellariou-Thompson, BS; Yunfei Wang; Ana Lucía Dominguez; Rafet Basar; Christopher Reyes; Sanjay Kumar; Larissa A. Meyer; Patrick Hwu; Chantale Bernatchez, PhD; Amir Jazaeri, MD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
173 Poster Presentation Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells Michelle Fleury, PhD; Derrick P. McCarthy, PhD; Holly Horton, PhD; Courtney Anderson, PhD; Amy Watt; Adam Zieba, MS; Lindsay Webb, PhD; Jian Ding, PhD; Robert Tighe; Robert Hofmeister, PhD; Dario Gutierrez, PhD Cellular Therapies Cytokine;Solid tumors;T cell
174 Poster Presentation Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes Meredith Frank, MSc; Parin Shah; Marie Andree Forget, PhD; Lorenzo Federico, PhD; Peixin Jiang; Roohussaba Khairullah; Ignacio Wistuba, MD; Chi-Wan Chow; Yan Long; Junya Fujimoto; Shiaw-Yih Lin, Ph.D.; Anirban Maitra, MBBS; Marcelo V. Negrao, MD; Kyle Mitchell, MD; Annika Weissferdt, MD; Ara A. Vaporciyan, MD; Tina Cascone, MD, PhD; Jack Roth; Jianjun Zhang, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Cara Haymaker, PhD; Daniel J. McGrail, PhD; Chantale Bernatchez, PhD; Alexandre Reuben, PhD Cellular Therapies Adoptive immunotherapy;Clinical study;Neoantigens;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
175 Poster Presentation High-dose TIL product with improved phenotype and functionality Christina Friese, PhD; Christina Heeke, PhD; Nikolaj Kirketerp-Møller, MS; Sandra Færch; Maria Juul Nielsen; Amalie Hey, PhD; Ulrik Cordes Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
176 Poster Presentation Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy Brian Halbert, MD MPH; David Einstein, MD; David F. McDermott, MD; Emanuelle I. Andrianopoulos; Mamta Gupta, MD; Virginia Seery, MSN, RN, ANP-BC; Kenneth Onimus; Courtney Herman; Adrian Wells; Shwetha Lakshmipathi; Arvind Natarajan; Anand Veerapathran; Rupal Bhatt, MD, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs)
177 Poster Presentation Treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibition–refractory advanced cutaneous melanoma Robert E. Hawkins, MD, PhD; Yizhou Jiang; Paul C. Lorigan; Fiona C. Thistlethwaite; Manon Pillai; Martine Thomas; Natalia Kirillova; John S. Bridgeman; Gray Kueberuwa; Ryan D. Guest; Zachary J. Roberts Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
178 Poster Presentation Expansion of Tumor-Infiltrating Lymphocytes and Marrow-Infiltrating Lymphocytes from Pediatric Malignant Solid Tumors Jonathan Metts, MD; Jonathan A. Hensel, PhD; Alejandro Alfaro; Brook Olmo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD; Ivanna Leon Cellular Therapies Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell
179 Poster Presentation CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity Jonathan A. Hensel, PhD; Alejandro Alfaro; Mary Rau; Patricio Perez-Villarroel; Zachary Sannasardo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
180 Poster Presentation T Cell Phenotype Drives Restructuring of Tumor Microenvironment to Balance T Cell Longevity and Tumor Control: Insights from Multiplexed Imaging and Multi-scale Agent Based Modeling John W. Hickey, PhD; Garry P. Nolan, PhD; Markus Covert; Eran Agmon; Nina B. Horowitz, MS; John B. Sunwoo, MD Cellular Therapies Adoptive immunotherapy;Bioinformatics;CAR T cells;Immune contexture;Immune monitoring;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
181 Poster Presentation Intraepithelial group 1 innate lymphoid cells generated in vitro exhibit enhanced cytotoxicity and infiltration into solid tumoroids Nina B. Horowitz, MS; John W. Hickey, PhD; John B. Sunwoo, MD Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs)
183 Poster Presentation Therapeutic T cells exhibit distinct vulnerability to glucose deprivation in tumors which can be overcome with an engineered glucose transporter Jessica A. Jana, BSE; Yiyang Wang, N/A; Ashley Menk, MS; Andrew Frisch, BS; Greg M. Delgoffe, PhD Cellular Therapies Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
184 Poster Presentation Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers Peter Kim, PhD; Steven A. Rosenberg, MD, PhD; Nolan Vale Cellular Therapies Adoptive immunotherapy;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs)
185 Poster Presentation Ex vivo efficacy of adoptive T cell therapy using autologous CD8+ T cells isolated by PD-1 positivity from peripheral blood mononuclear cells in solid tumors Sungkyu Lee, Ph.D; yong wha Moon Cellular Therapies Adoptive immunotherapy;Coinhibition;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
186 Poster Presentation Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 Karrie K. Wong, PhD; Sharon Lin, PhD; Christopher Wrocklage; Katri Sofjan; Leila Williams; Mallory Brady; Nicholas Colletti, PhD; Noah Tubo; Hugh Gannon; Robert A. LaMothe; Tianlei Xu, PhD; Tracy VandenBerg; Sol Shenker, PhD; Caroline Dugopolski; Frank Stegmeier, PhD; Louise Cadzow; Michael Schlabach, PhD; Micah J. Benson, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
187 Poster Presentation Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival Melisa Angela M. Paniagua, PhD; Melisa A. Martinez Paniagua, PhD; Cara Haymaker, PhD; Jay R Adolacion; Xingyue An, BS; Caitlin Creasy, MS; Mohsen Fathi; Ali Rezvan; Tamar Geiger; Michal Harel; Jonathan Robinson; Amit Amritkar; Scott Woodman; Patrick Hwu; Chantale Bernatchez, PhD; Navin Varadarajan, PhD Cellular Therapies Adoptive immunotherapy;Gene expression;Metabolism;Proteomics;RNA;Tumor infiltrating lymphocytes (TILs)
188 Poster Presentation Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity. Ryan Sullivan, PhD; Mary Mathyer; Jennifer Govero; John Dean; Andrew Martens; You Zhou; Malik Darwech; Brunda Tumala; Alex Vessoni; Alexander Hamil; Tom Leedom; Corey Johnson; Melissa Berrien-Elliot; Mark Foster; Michelle Becker-Hapak; Ethan McClain; Carly Neal; Todd A. Fehniger, MD, PhD; Niraj Shrestha, PhD; Mike Dee; Hing C. Wong, PhD; Ayman Kabakibi; Matthew L. Cooper; Ken Chrobak Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;T cell
189 Poster Presentation Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer Justyna Ogonek, PhD; Justyna Ogonek; Tiziana Franceschetti; Andreas Acs; Alexander Schmidt; Alexandra Kuhlenkamp; Krystel Vincent; Claude Perreault; Barbara Loesch; Adriana Turqueti Neves; Slavoljub Milosevic; Dolores J. Schendel; Daniel Sommermeyer Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens
190 Poster Presentation Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers Anup Y. Parikh, MD; Maria Parkhurst, PhD; Paul F. Robbins, PhD; Steven A. Rosenberg, MD, PhD; James C. Yang, MD, PhD Cellular Therapies Adoptive immunotherapy;Gene expression;Neoantigens;RNA;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs)
191 Poster Presentation GAPDH knock-in of high affinity CD16 in iPSC derived NK cells drives high-level expression and increased anti-tumor function Rithu Pattali; Kaitlyn M. Izzo; Edward J. Goncz; Steven Sexton; Kevin M. Wasko; John A. Zuris, Ph.D.; Michael Nehil, Ph.D.; Kate Zhang, Ph.D.; Mark Shearman, Ph.D.; Kai-Hsin Chang, Ph.D.; Alexander G. Allen, Ph.D. Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Solid tumors
192 Poster Presentation POoled T Cell Receptor Screening (POTS) Provides Unbiased, High-Throughput Method for TCR Discovery Jack L. Reid, BSc; Shihong Zhang, Ph.D; Ariunaa Munkhbat; Matyas Ecsedi, MD, PhD; Megan S. McAfee, PhD; Aude Chapuis, MD Cellular Therapies Adoptive immunotherapy;T cell;Tumor antigens
193 Poster Presentation The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies Eleni Kotsiou, PhD; Joe Robinson; Amber Rogers; Daisy Melandri; Amy Baker; Anabel Ramirez Aragon; Sidra Nawaz; Michael Epstein; Shreenal Patel; Jennine Mootien; Andrew W. Craig, PhD; Satwinder Kaur-Lally; Hinal Patel; Andreas Schmitt; Farah Islam; Mariam Jamal-Hanjani; David Lawrence; Martin Foster; Samra Turajlic, MD PhD; Sergio A. Quezada, PhD; Katy Newton, BSc PhD Cellular Therapies Adoptive immunotherapy;Dendritic cell;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
195 Poster Presentation Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy Renata AM. Rossetti, PhD; Leticia Tordesillas; Matthew Beatty, PhD; Yian Ann Chen; Dongliang Du; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD; Daniel Abate-Daga, PhD Cellular Therapies Adoptive immunotherapy;B cell;Solid tumors;Tumor infiltrating lymphocytes (TILs)
196 Poster Presentation TLR9-activated B cells directly license adoptively transferred CD8+ T cells with potent tumor immunity Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Brandon Ware, PhD; Amalia M. Rivera Reyes, BS; Connor J. Dwyer, PhD; David M. Neskey, MD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Chrystal M. Paulos, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;B cell;Costimulation;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs)
197 Poster Presentation Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells Kristin M. Snyder, DVM/PhD Student; Kate Dixon, PhD; Melissa Khaw; Zachary B. Davis, PhD; Paul Rogers, PhD; Martin Hosking, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Jianming Wu, DVM/PhD; Bruce Walcheck, PhD Cellular Therapies Antibody;NK/NKT cell;Solid tumors
198 Poster Presentation Costimulatory antigen receptor (CoStAR): a novel platform that enhances the activity of tumor infiltrating lymphocytes (TILs) Sujita Sukumaran, PhD; Milena Kalaitsidou; Michelle Mojadidi; Clare Yarka; Yong (Stella) Ouyang; Eric Gschweng; Gray Kueberuwa; John S. Bridgeman, PhD; Bob Hawkins; Rubén Alvarez-Rodríguez Cellular Therapies Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
199 Poster Presentation Potent T cell costimulation mediated by a novel costimulatory antigen receptor (CoStAR) with dual CD28/CD40 signaling domains to improve adoptive cell therapies Martina Sykorova; Leyuan Bao; Cynthia Chauvin-Fleurence; Milena Kalaitsidou; Michelle Le Brocq; Robert E. Hawkins, MD, PhD; Gray Kueberuwa; John S. Bridgeman, PhD; Rubén Alvarez-Rodríguez Cellular Therapies Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
200 Poster Presentation TGFβ-Armoring Boosts Potency and Persistence of Engineered TCR T Cells, Unlocking Superior Efficacy Against HPV-positive Solid Tumors Gail D. Turner, PhD; Gabriela Diaz, BS; Andreia Costa, PhD; Yeonjoo Oh, MS; Jianguo Huang, PhD; Jenna Bailey, BS; Cyr C. De Imus, BS; Stephanie E. Busch, PhD; Teresa Foy, PhD; Pallavur Sivakumar, PhD; Ruth A. Salmon, PhD; Cédric Cleyrat, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor microenvironment
201 Poster Presentation BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer Christina Arieta, PhD; Diana Velez, MS; Susan B. Hannes, BS; Shirisha Meda, MS; Brian McCarthy; Divya R. Lenkala, MS; Dewi Harjanto; Prerna Suri; Jessica Kohler, PhD; Jonathan McGee; Daniel Kallin; Paul Turcott; Cynthia Nijenhuis; Maarje W. Rohaan; Gabe Sonke; John B. Haanen, MD; Mark DeMario, MD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD Cellular Therapies Adoptive immunotherapy;Neoantigens;RNA;T cell
202 Poster Presentation In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells Ruipeng Wang, PhD; Lauren Suarez, PhD; Emily Lu, PhD; Pratima Kunwar, PhD; Daniel Dembrow; Sojung Kim, PhD; Mathias Oelke, PhD Cellular Therapies Antigen presenting cells;Solid tumors;T cell;Targeted therapy;Tumor antigens
203 Poster Presentation A Membrane-Tethered IL-15/IL-15 Receptor Fusion Protein Enhances the Persistence and Efficacy of CD70-Targeted TRuC-T Cells Jian Ding, PhD; Lindsay Webb; Troy Patterson; Michelle Fleury, PhD; Adam Zieba, MS; Holly Horton, PhD; Robert Hofmeister, PhD; Dario Gutierrez; Robert Tighe, NN Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
204 Poster Presentation KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors Karrie K. Wong, PhD; Christopher Wrocklage; Sharon Lin, PhD; Isabelle Le Mercier, PhD; Caroline Bullock; Louise Cadzow; Anja Hohmann, PhD; Sol Shenker, PhD; Katri Sofjan; Leila Williams; Gregory Kryukov, PhD; Conor Calnan; Frank Stegmeier, PhD; Micah J. Benson, PhD; Michael Schlabach, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
205 Poster Presentation agenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models Burcu Yigit, PhD; Darrian Moskowitz; Xavier Michelet, PhD; Antoine Tanne, PhD; Marc A. Van Dijk, PhD Cellular Therapies Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;T cell
206 Poster Presentation The development of 'chimeric CD3e fusion protein' and 'anti-CD3-based bispecific T cell activating element' engineered T (CAB-T) cells for the treatment of solid malignancies Andy Tsun, PhD; Zhiyuan Li; Zhenqing Zhang; Weifeng Huang; Shaogang Peng; Jitian Chai Cellular Therapies Antibody;Bispecifics;CAR T cells;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
207 Poster Presentation Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells Daniel Corey, MD; Sunil Thomas, PhD; Brandon Cieniewicz, PhD; Linh Nguyen, PhD; Jared Clever, PhD; Josephine Brysting, BS; Remus Vezan, MD PhD; John M. Rossi, MS; Kurt Diem, PhD; Lei Jin, PhD; Lawrence Corey, MD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Costimulation;Dendritic cell;Leukemia/Lymphoma;Monocyte/Macrophage;T cell;TLR;Tumor evasion
208 Poster Presentation RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice Anne-Sophie Dugast, PhD; Shannon L. McArdel; Zafira Castano; Maegan E. Hoover; Arjun Reddy Bollampalli; Enping Hong; Shannon Leonard; Ryan Pepi; Alex Nanna; Laurence A. Turka; Sivan Elloul Cellular Therapies Costimulation;Cytokine;Monocyte/Macrophage;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs)
209 Oral Presentation Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity Sabina Kaczanowska, PhD; Daniel Beury, PhD; Haiying Qin, MS; Rosandra N. Kaplan, MD Cellular Therapies Adoptive immunotherapy;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;Tumor microenvironment
210 Poster Presentation A novel medium for increased cytotoxicity and serum-minimal ex vivo expansion of natural killer (NK) cellular immunotherapies Marc A. Gillig, PhD; Graeme Lambert; Donna Sonntag; Rachit Ohri, Ph.D.; Jason G. Cahoon, BS; Avishai Shemesh, PhD; Nadhim A. Mukhaiter, MS Cellular Therapies Adoptive immunotherapy;NK/NKT cell
211 Poster Presentation SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines Michael F. Maloney, PhD; Emrah Ilker Ozay, PhD; Amy Merino; Andrea A. Silva; Amber M. Martin, MS; Sanjana Manja, MS; Madhav Upadhyay, MS; Christine Trumpfheller, PhD; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD Cellular Therapies Antigen presenting cells;Costimulation;Cytokine;RNA;Solid tumors;T cell;Tumor antigens;Vaccine
212 Poster Presentation Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates Amanda Nash; Maria Jarvis, PhD; Samira Aghlara-Fotovat; Sudip Mukherjee, PhD; Andrea Hernandez; Andrew Hecht; Peter Rios, PhD; Sofia Ghani; Ira Joshi; Douglas Isa; Yufei Cui; Shirin Nouraein; Jared Lee; Chunyu Xu; David Zhang, PhD; Rahul Sheth, MD; Weiyi Peng, PhD; Jose Oberholzer, MD; Oleg Igoshin, PhD; Amir Jazaeri, MD; Omid Veiseh, PhD Cellular Therapies Cytokine;Immune toxicity;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
213 Poster Presentation AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells Stephen Santoro, PhD; Aaron Cooper, PhD; Natalie Bezman, PhD; Jun Feng, PhD; Kanika Chawla, PhD; Jaspar Williams, PhD; John Gagnon, PhD; Jason Hall, PhD; Dina Polyak, PhD; Angela Boroughs, PhD; Michelle Nguyen; Suchismita Mohanty, PhD; Adam Litterman, PhD; Jeff Granja; David DeTomaso, PhD; Grace Zheng, PhD; Jenessa Smith, PhD; Drake LeFace, PhD; Tarjei Mikkelsen, PhD; Susie Jun, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor microenvironment
214 Poster Presentation SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma Zhen Bian, PhD; Lei Shi, PhD; Koby Kidder, PhD; Yuan Liu, MD PhD Cellular Therapies Antigen presenting cells;Immune suppression;Monocyte/Macrophage;Myeloid cells;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
215 Poster Presentation Tissue-resident natural killer cells resembling intraepithelial ILC1 have potent anti-tumor activity in human head and neck cancer and represent a novel class of effector cells for immunotherapy JuneHo JS. Shin, Ph; Nina B. Horowitz, MS; Quan L. Tran; Chen Chen; Uriel Y. Moreno-Nieves, PhD; Joshua K. Tay, MD PhD; Saumyaa Saumyaa; John B. Sunwoo, MD Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
216 Oral Presentation Multiplex base editing of NK cell to enhance cancer immunotherapy Minjing Wang, BSc; Mitchell G. Kluesner, BSc; Patricia N. Claudio Vázquez, BSc; Beau R. Webber, PhD; Branden S. Moriarity, PhD Cellular Therapies Gene expression;NK/NKT cell
217 Poster Presentation Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabolome Dima DY. Yackoubov, MSc; Aviad Pato; Julia Rifman, PhD; Sherri Cohen; Astar Hailu; Nurit Brycman; Orit Berhani-Zipori, PhD; Avishay Edri, PhD; Boaz Buhandler; Moshe Shahor; Nathan Dinowitz; Amram Ben David; Avi Izraeli; Vered Chalifa-Caspi, PhD; Liron Levin, PhD; Joshua D. Rabinowitz, Prof.; Wenyun Lu, PhD; Tracey Lodie, PhD; Julian Adams, PhD; Yona Geffen, PhD Cellular Therapies Adoptive immunotherapy;Bioinformatics;Biomarkers;Gene expression;Leukemia/Lymphoma;Metabolism;NK/NKT cell;Proteomics
218 Poster Presentation Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses Jenny Zilberberg, Ph.D.; Amelia Zellander, Ph.D.; Kenneth Kirby, M.S.; Christopher Uhl, Ph.D.; Christopher Cultrara, Ph.D.; Charles Scott, Ph.D.; David Andrews, M.D.; Mark Exley, Ph.D.; Mark Exley, MS, Ph.D. Cellular Therapies Cytokine;Immune adjuvant;T cell;Tumor antigens;Vaccine
219 Poster Presentation CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001 Haoxiao Zuo; Satwinder Kaur Singh, PhD; Marie-José Van Lierop; Jorn Kaspers; Remco Bos; Alwin Kamermans; Helga E. de Vries; Tanja D. de Gruijl, PhD; Ada M. Kruisbeek, PhD; Erik Manting Cellular Therapies Antigen presenting cells;Chemokine;Cytokine;Dendritic cell;Immune adjuvant;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Tumor antigens;Vaccine
220 Poster Presentation Transfection of human adipose-derived mast cells: A characteristic study using different chemical reagents Mona Motaghed, PhD Candidate; Christopher Kepley, Ph.D.; Kristen Dellinger, Ph.D.; Elnaz Ahani, Ph.D. Candidate; Mohammad Fereydouni, Ph.D. Candidate Cellular Therapies Adoptive immunotherapy;Gene expression;Monocyte/Macrophage
221 Oral Presentation CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors Rebecca C. Larson, BS; Michael Kann; Stefanie R. Bailey, PhD; Nicholas J. Haradhvala; Kai Stewart; Amanda Bouffard; Irene Scarfo; Mark Leick; Trisha R. Berger; Max Jan; Julia Joung; Tamara Ouspenskaia; Travis Law; Aviv Regev, PhD; Gad Getz, PhD; Marcela V. Maus, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Solid tumors
222 Poster Presentation Genetic reprogramming of Merkel cell carcinoma and melanoma leads to increased MHC-I expression and antitumor immune activation in vitro and in vivo Kathryn M. Luly, BS; Jordan J. Green, PhD; Stephany Y. Tzeng, PhD; Joel C. Sunshine, MD, PhD Cellular Therapies Costimulation;Cytokine;Immune adjuvant;NK/NKT cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
223 Poster Presentation Potent inhibition of PI3Kδ promotes enhanced T cell stemness and mitochondrial fitness Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Anna C. Cole, BA; Megan M. Wyatt, MS; Brandon Ware, PhD; Chrystal M. Paulos, PhD Cellular Therapies Adoptive immunotherapy;Immune adjuvant;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
224 Poster Presentation M2 macrophage-mediated immune suppression of chimeric antigen receptor T cells via PD-L1 signaling in prostate cancer Yukiko Yamaguchi; Jackson Gibson; Kevin Ou; Saul Priceman, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors
225 Poster Presentation Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs Ioannis IG. Gavvovidis, PhD; Matthias Leisegang, Prof. Dr.; Vivian Scheuplein, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Elisa Kieback, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor antigens
226 Poster Presentation Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers Ana B. Korngold, PhD; Jean Lin-Kin Yong, PhD; Ugochi C. Ibekwe; Julissa Simmons; Phillip Eckels, MPH; Elizabeth Figueroa, PhD; Michelle Hotard; Frances Adeyemi; Thomas Hunt; Tegan Markus; Lenka V. Hurton, PhD; Yaoyao Shi, PhD; Matthew R. Collinson-Pautz, PhD; Priya Balasubramanian, PhD; Cathy Wang, PhD; Jourdan Andersson, PhD; Lauren Heese; Mariam Khalil; David Torres; Emarco Olivares; Geraldine Bardelli; Kelly O'Brien, PhD; Haroon Hashmi; Alena Chekmasova; Raffaele Baffa, MD; Tom Spencer, PhD; Eleanor De Groot, PhD; Drew C. Deniger, PhD Cellular Therapies Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens

Late-Breaking

946 Poster Presentation Standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration Sarah E. Church, PhD; Christina M. Bailey, MS; Sarah E. Warren, PhD; Lisa H. Butterfield, PhD; Cellular Therapies RNA;Adoptive immunotherapy;Bioinformatics;Biomarkers;CAR T cells;Gene expression;Immune monitoring;Immune toxicity;Leukemia/Lymphoma;Solid tumors